دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux?Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
doi : 10.1002/acr2.11259
ACR Open Rheumatol. 2021 Aug; 3(8): 501–511.
To investigate the impact of baseline and time?varying factors on the risk of serious adverse events (SAEs) in patients during long?term certolizumab pegol (CZP) treatment.
Associations of Comorbid Conditions and Transitions Across States of Knee Osteoarthritis in a Community?Based Cohort
Yvonne M. Golightly, Carolina Alvarez, Liubov S. Arbeeva, Rebecca J. Cleveland, Todd A. Schwartz, Jordan B. Renner, Louise B. Murphy, Leigh F. Callahan, Joanne M. Jordan, Amanda E. Nelson
doi : 10.1002/acr2.11287
ACR Open Rheumatol. 2021 Aug; 3(8): 512–521.
To examine relationships between knee osteoarthritis (KOA) and obesity, diabetes mellitus (DM), and cardiovascular disease (CVD).
Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study
Carol A. Hitchon, Girsh M. Mody, Candace H. Feldman, Yan Lau, Steven Shi, Michele Meltzer, Rosie Scuccimarri, Michael E. Weinblatt, Ines Colmegna
doi : 10.1002/acr2.11290
ACR Open Rheumatol. 2021 Aug; 3(8): 522–530.
Guidelines for methotrexate (MTX) use in rheumatic disease may not be feasible for physicians practicing in the least developed countries. We aimed to understand the experiences of MTX prescribers relating to MTX use for rheumatic disease in African countries to inform the development of culturally and geographically appropriate recommendations.
Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease?Modifying Antirheumatic Drugs
Ajinkya Pawar, Rishi J. Desai, Mengdong He, Lily Bessette, Seoyoung C. Kim
doi : 10.1002/acr2.11292
ACR Open Rheumatol. 2021 Aug; 3(8): 531–539.
The objective of this study was to compare the incidence rate of nonvertebral osteoporotic fractures (NVFs) in patients with rheumatoid arthritis (RA) initiating one of the nine biologic or targeted synthetic disease?modifying antirheumatic drugs (b/tsDMARDs).
Nutrition Information Resources Used by People With Systemic Sclerosis and Perceived Advantages and Disadvantages: A Nominal Group Technique Study
Nora ?stb?, Elizabeth Y. Jimenez, Sami Harb, Angelica Bourgeault, Marie?Eve Carrier, Brett D. Thombs, the Scleroderma Patient?Centered Intervention Network (SPIN) Diet and Nutrition Education Patient Advisory Team
doi : 10.1002/acr2.11293
ACR Open Rheumatol. 2021 Aug; 3(8): 540–549.
Where people with systemic sclerosis (SSc) (or scleroderma) obtain diet and nutrition information to manage their disease is not known. Objectives were to identify 1) resources used by people with SSc for nutrition and diet information and 2) perceived advantages and disadvantages of resources.
Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz
doi : 10.1002/acr2.11267
ACR Open Rheumatol. 2021 Aug; 3(8): 550–557.
Patients with systemic lupus erythematosus (SLE) are usually treated with glucocorticosteroids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid withdrawal was associated with an increased likelihood of flare in the next 12 months. The aim of the present study was to assess clinical flare rates and damage accrual in patients who tapered glucocorticosteroids gradually.
The Prevalence of Knee Symptoms, Radiographic, and Symptomatic Osteoarthritis at Four Time Points: The Johnston County Osteoarthritis Project, 1999?2018
Amanda E. Nelson, David Hu, Liubov Arbeeva, Carolina Alvarez, Rebecca J. Cleveland, Todd A. Schwartz, Louise B. Murphy, Charles G. Helmick, Leigh F. Callahan, Jordan B. Renner, Joanne M. Jordan, Yvonne M. Golightly
doi : 10.1002/acr2.11295
ACR Open Rheumatol. 2021 Aug; 3(8): 558–565.
To describe point prevalence of knee symptoms, radiographic knee osteoarthritis (rKOA), severe rKOA, and symptomatic rKOA at four time points in the longitudinal, population?based Johnston County Osteoarthritis Project (JoCo OA).
Appendicular Lean Mass, Grip Strength, and the Development of Knee Osteoarthritis and Knee Pain Among Older Adults
James S. Andrews, Laura S. Gold, Michael Nevitt, Patrick J. Heagerty, Peggy M. Cawthon
doi : 10.1002/acr2.11302
ACR Open Rheumatol. 2021 Aug; 3(8): 566–572.
The association of sarcopenia with development of knee osteoarthritis (OA) or knee pain in older adults is uncertain. We examined the relationship of grip strength and appendicular lean mass (ALM) with the likelihood of developing knee OA and knee pain in older adults in the Health ABC (Health, Aging, and Body Composition) Study.
Prescription Opioids Higher Among Knee Arthroplasty Recipients Randomized to Inpatient Rehabilitation
Justine M. Naylor, Mark Buhagiar, Nathan Johns, Jonathan Penm, Sam Adie, Ian A. Harris, Wei Xuan
doi : 10.1002/acr2.11304
ACR Open Rheumatol. 2021 Aug; 3(8): 573–577.
To determine whether the purchase of prescription opioids was lower among people randomized to inpatient rehabilitation (IR) compared with those discharged directly home following total knee arthroplasty (TKA).
Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?
Can M. Sungur
doi : 10.1002/acr2.11303
ACR Open Rheumatol. 2021 Aug; 3(8): 578–580.
With increasing numbers of patients with rheumatoid arthritis achieving sustained remission, medication withdrawal is an important consideration to reduce polypharmacy and associated adverse events. An article from the journal Arthritis & Rheumatology (1) explores the treatment withdrawal options for patients on etanercept and methotrexate combination therapies and suggests methotrexate withdrawal has the least impact on disease worsening. There are limitations in the study, including the use of only one disease activity score and no assessment of radiographic progression, but, overall, the article provides a good framework for future studies on treatment withdrawal options and the possibility of medication reduction for patients.
